include the following: the internal thoracic-superior-inferior epigastric veins on the left; the lateral thoracicsuperficial epigastric veins on the right; the anterior and posterior intercostal veins; the azygos-accessory hemiazygos-hemiazygos veins; the jugular veins; the vertebral plexus; and the small tributaries of the thoracoabdominal wall and the breast. 4, 5 On radionuclide venography, the lateral thoracic veins, the internal thoracic veins, the accessory hemiazygos veins, and the azygos veins can be seen running vertically (with the latter two veins being medially located), while the intercostal veins run horizontally. 4 The superficial collateral flow via the small tributaries of the chest wall can be visualized on chest inspection and by contrast chest CT scan as dilated veins over the anterior chest wall. Dilated superficial veins of the breast that provide collateral flow have been visualized by mammography. 5 In this patient, we have described the presence of dilated superficial veins of the breast, which were first noted on routine mammography, served to alert the physician to a possible SVCO. As a result, a radionuclide superior venacavagram was performed, and the diagnosis of SVCO was established.
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In patients with chronic SVCO, the development of collateral venous pathways that bypass the obstructed superior vena cava can make SVCO clinically occult. In such cases, only the visualization of these collateral pathways will suggest the unanticipated diagnosis of SVCO. Our experience is unique in that a routine mammogram served this purpose. 
Pamidronate Results in

Case Report
We report the case of a 27-year-old woman with CF who presented with severe diffuse bone pain and HPOA, which responded to therapy with IV pamidronate. The patient had moderate bronchiectasis (FEV 1 , 65% of predicted), and chronic Pseudomonas aeruginosa infection. The treatment of pulmonary disease included physiotherapy, therapy with aerosolized bronchodilators, therapy with intermittent nebulized aminoglycosides, and two previous hospital admissions for therapy with IV antibiotics. The patient was well-nourished (body mass index, 24.6 kg/m 2 ), but a liver biopsy had confirmed the presence of biliary cirrhosis, which was complicated by portal hypertension (ie, splenomegaly, thrombocytopenia, and esophageal varices, which had been controlled with sclerotherapy).
In June 1999, the patient presented with an 8-week history of severe bilateral ankle and knee pain, and right elbow and right wrist pain. The pain was being poorly controlled with simple analgesia and was impairing the patient's sleep at night. The pain was associated with severe early-morning stiffness and required leave from full-time employment as a clerical officer. A clinical examination revealed bony tenderness proximal to both ankles, which was associated with minimal ankle edema. There was no clinical evidence of synovitis or of an inflammatory arthritis. The findings of chest and abdominal examinations were unchanged from those of earlier examinations, and the results of spirometry testing were consistent with earlier values. Rheumatoid factor was negative, and antinuclear antibody level was weakly positive (nucleolar pattern, titer 160; the normal reference is Ͻ40 titre). How-ever, the results of tests for double-stranded DNA, extractible nuclear antigen, and antineutrophil cytoplasmic antibodies were negative. A radiograph demonstrated bilateral periosteal reaction and eccentric calcification of the distal radius, fibula, and tibia, which were consistent with the presence of HPOA (Fig 1) . An isotopic bone scan confirmed increased activity at the margins of the distal radius and tibia.
In view of the complications of portal hypertension, varices, and thrombocytopenia, therapy with NSAIDs was avoided. Rapid relief of bone pain and joint stiffness was obtained with oral prednisolone (50 mg/d) therapy, but the symptoms recurred as before when the dose was reduced to Ͻ 7.5 mg/d. Therefore, 5 months after presentation, IV pamidronate (30 mg) was administered following a 48-h increase in the prednisolone dose to 40 mg/d. Pamidronate was not complicated by increased bone pain, and all symptoms resolved completely within 72 h of the infusion, allowing a rapid reduction in the prednisolone dose. No other side effects were seen following administration of pamidronate. Four subsequent infusions of pamidronate have been administered following the recurrence of severe bone pain, at intervals of 10 to 16 weeks after the previous infusions, with complete relief of symptoms, which allowed the patient to return to full-time employment. The patient has continued to receive low dose, alternate-day prednisolone therapy and is currently receiving 5 mg on alternate days, with the aim of weaning the dose to zero.
The patient's pulmonary status has been complicated by one episode of bilateral pneumonia and by a parapneumonic effusion, which required inpatient IV antibiotic therapy for 3 weeks in May 2000. Subsequently, the results of spirometry testing returned to normal values.
Discussion
HPOA is a relatively uncommon but potentially disabling complication of CF. It occurs in 2 to 7% of patients with CF, usually in older patients with advanced lung disease. 1 Symptoms associated with HPOA may be controlled by therapy with NSAIDs or corticosteroids. In view of coexisting hepatic disease and concerns about the morbidity associated with long-term therapy with high-dose corticosteroids, further options were considered. The recently released cyclooxygenase-2 inhibitor drugs (eg, celecoxib) were not available at the time of the initiation of biphosphonate therapy, and no data are available regarding the safety or efficacy of its administration in patients with HPOA.
We report for the first time the use of biphosphonate therapy in a case of refractory HPOA in a patient with CF. Disodium pamidronate is a potent inhibitor of osteoclastic bone resorption, which is thought to be responsible for its therapeutic effect. Pamidronate has been used to treat conditions with increased osteoclastic activity, including lytic bony metastatic malignancy, advanced multiple myeloma, tumor-induced hypercalcemia, and symptomatic Paget disease of the bone. The activation of endothelial cells and platelets occurring with neovascular proliferation appears to be a key feature of HPOA that may contribute to increased osteoclastic activity. 2 Bisphosphonate therapy has been demonstrated to be effective in achieving symptom control in patients with HPOA complicating advanced lung cancer. 3 IV pamidronate therapy has been effective in controlling bone pain in patients with HPOA complicating CF without significant morbidity. The lack of severe bone pain following pamidronate infusion in our patient, who was receiving corticosteroids, parallels information from other reports. 4, 5 While response to IV bisphosphonates has been encouraging, repeated courses of pamidronate may be required to maintain symptom control.
